$IVF Unusual they adjusted the authorized shares for the reverse split. Prepping for a buyout perhaps? Typically I’ve seen companies leave their A/S post reverse. Any thoughts?
$IVF Interesting for a valuation perspective. IVF companies getting valued and bought out around 8-9x earnings. Medical patent excluded that would put INVO valuation about $90m from a buyout perspective
https://t.co/V5Dd94RBJ1
@thommic I saw some potential dilution on the table but this is excessive. It was about 8m shares and the total OS would still be only 15m. Not sure why they would be dumping at all time lows.
$IVF Just the beginning
The Company achieved strong 23% organic growth during the quarter driven by added increased patient flow at its Wisconsin and Georgia clinics.
$IVF Patented
Device Expansion: The Company has expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology, resulting in 130% year-over-year growth in INVOcell device revenue.
$IQST 17m market cap and projected to pull in $400m+ yearly revenue.
Shares Outstanding: 3,832,470 as of September 30, 2025
Projected growth rate super positive.